Stoppe, Christian; Hill, Aileen; Cancio, Leopoldo C.; Day, Andrew G.; Pruskowski, Kaitlin A.; Turgeon, Alexis F.; Pham, Tam; Bélisle, Sylvain; Martínez-Jiménez, Mario Aurelio; Limper, Ulrich; Gille, Jochen; Wisler, Jon; Savetamal, Alisa; Pollack, Jonathan; Grau Domínguez, Daisy; Jennes, Serge; Shupp, Jeffrey W.; Jeschke, Marc G.; Colpaert, Kirsten; Hundeshagen, Gabriel; Beier, Justus P.; Muangman, Pornprom; Echeverri McCandless, Ann; Meybohm, Patrick; Grune, Tilman; Dresen, Ellen; Weber, Daniela; Güttler, Carina; Lew, Charles Chin Han; Jiang, Xuran; Froese, Shawna; Dansereau, Maureen; Lee, Zheng-Yii; Heyland, Daren K.
doi: 10.1001/jama.2026.10616pmid: N/A
Key PointsQuestionDoes high-dose intravenous vitamin C reduce a composite of 28-day mortality and persistent organ dysfunction in patients with severe burn injury? FindingsIn this randomized clinical trial that included 238 patients with severe burns, the primary composite outcome of 28-day mortality and persistent organ dysfunction occurred in 40.8% of patients in the intravenous vitamin C group compared with 29.7% in the placebo group. At the first prespecified interim analysis, this result crossed the futility/harm threshold, prompting early termination of the trial. MeaningHigh-dose intravenous vitamin C did not reduce mortality and organ dysfunction and may be associated with harm in patients with severe burn injury.